PT Charlie Hospital Semarang Tbk
PT Charlie Hospital Semarang Tbk operates in the private hospital business in Indonesia. The company offers medical services and support, inpatient, and medical check-up services, as well as operates wellness center. The company was founded in 2019 and is based in Kendal, Indonesia. PT Charlie Hospital Semarang Tbk is a subsidiary of PT Wahyu Agung.
PT Charlie Hospital Semarang Tbk (RSCH) - Net Assets
Latest net assets as of September 2025: Rp132.06 Billion IDR
Based on the latest financial reports, PT Charlie Hospital Semarang Tbk (RSCH) has net assets worth Rp132.06 Billion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp276.94 Billion) and total liabilities (Rp144.88 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp132.06 Billion |
| % of Total Assets | 47.69% |
| Annual Growth Rate | 97.71% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 151.45 |
PT Charlie Hospital Semarang Tbk - Net Assets Trend (2022–2024)
This chart illustrates how PT Charlie Hospital Semarang Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PT Charlie Hospital Semarang Tbk (2022–2024)
The table below shows the annual net assets of PT Charlie Hospital Semarang Tbk from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp146.96 Billion | -2.33% |
| 2023-12-31 | Rp150.46 Billion | +300.57% |
| 2022-12-31 | Rp37.56 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to PT Charlie Hospital Semarang Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 462427819000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rp132.50 Billion | 90.16% |
| Other Components | Rp31.50 Billion | 21.44% |
| Total Equity | Rp146.96 Billion | 100.00% |
PT Charlie Hospital Semarang Tbk Competitors by Market Cap
The table below lists competitors of PT Charlie Hospital Semarang Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Workhorse Group Inc
NASDAQ:WKHS
|
$11.67 Million |
|
Silver Grant International Holdings Group Limited
F:YSG
|
$11.67 Million |
|
Seneca Financial Corp
PINK:SNNF
|
$11.67 Million |
|
HOLALUZ-CLIDOM SA EO 003
F:4H2
|
$11.67 Million |
|
Y. T. Realty Group Limited
PINK:YTRGF
|
$11.66 Million |
|
Arthavest Tbk
JK:ARTA
|
$11.66 Million |
|
LiqTech International Inc
NASDAQ:LIQT
|
$11.66 Million |
|
IT Link
PA:ALITL
|
$11.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PT Charlie Hospital Semarang Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 150,459,724,780 to 146,956,741,570, a change of -3,502,983,210 (-2.3%).
- Net loss of 3,512,480,090 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp-3.51 Billion | -2.39% |
| Other Changes | Rp9.50 Million | +0.01% |
| Total Change | Rp- | -2.33% |
Book Value vs Market Value Analysis
This analysis compares PT Charlie Hospital Semarang Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.26x to 6.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | Rp14.17 | Rp358.00 | x |
| 2023-12-31 | Rp56.78 | Rp358.00 | x |
| 2024-12-31 | Rp55.46 | Rp358.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PT Charlie Hospital Semarang Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.24%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.31x
- Recent ROE (-2.39%) is above the historical average (-7.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -19.58% | -22.26% | 0.36x | 2.42x | Rp-11.11 Billion |
| 2023 | -0.74% | -2.64% | 0.27x | 1.03x | Rp-16.16 Billion |
| 2024 | -2.39% | -7.24% | 0.25x | 1.31x | Rp-18.21 Billion |
Industry Comparison
This section compares PT Charlie Hospital Semarang Tbk's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $4,124,745,828,171
- Average return on equity (ROE) among peers: 28.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PT Charlie Hospital Semarang Tbk (RSCH) | Rp132.06 Billion | -19.58% | 1.10x | $11.66 Million |
| Bundamedik Tbk PT (BMHS) | $665.59 Billion | 4.71% | 1.10x | $23.76 Million |
| Metro Healthcare Indonesia (CARE) | $3.30 Trillion | 0.18% | 0.28x | $411.41 Million |
| Medikaloka Hermina PT (HEAL) | $2.37 Trillion | 5.25% | 0.76x | $810.80 Million |
| Lippo Karawaci Tbk (LPKR) | $23.57 Trillion | -40.88% | 1.20x | $179.43 Million |
| Mitra Keluarga Karyasehat Tbk PT (MIKA) | $3.28 Trillion | 17.29% | 0.13x | $602.27 Million |
| PT Murni Sadar Tbk (MTMH) | $50.49 Billion | 4.95% | 14.96x | $27.98 Million |
| Famon Awal Bros Sedaya (PRAY) | $3.13 Trillion | 6.43% | 0.62x | $52.90 Million |
| Royal Prima PT (PRIM) | $722.89 Million | 252.77% | 36.50x | $3.23 Million |
| Kedoya Adyaraya Tbk PT (RSGK) | $751.16 Billion | 3.35% | 0.10x | $3.08 Million |